Novo Nordisk says Wegovy approved in China for MASH

NVO•2026-09-10

Wegovy approved in China for MASH

STOCKHOLM, Sept 10 (Reuters) - Novo Nordisk said on Thursday that Wegovy has been approved in China as the first and only GLP-1 RA for the treatment of MASH.

Novo Nordisk says Wegovy approved in China for MASH

Wegovy approved in China for MASH

Related News

Nasdaq trade halt continues <OST.O> reason not available at 03:58 AM

South Korea nears agreement worth over $100 billion in US investments, WSJ reports

HSBC files HKEX next-day disclosure return on share buyback cancellation

Emerging Markets-Emerging Asia stocks slide, currencies tread water as oil tops $100

GS, JPM upgrade Fortum as it wins major deal as part of Google's AI investment